DexCom, Inc.

DexCom, Inc.

Compare this stock

DXCM Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarningsAnalyst Price Targets

62%

Performance

Score:

10/100

DXCM returned -13.23% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

76/100

18 analysts offer 12-month price targets for DXCM. Together, they have an average target of 75.37, the most optimistic target put DXCM at 146 within 12-months and the most pessimistic has DXCM at 28.12.

Technicals

Score:

68/100

DXCM receives a 67 of 100 based on 14 indicators. 9 are bullish, 4 are bearish.

Earnings

Score:

59/100

DXCM has missed earnings 2 times in the last 20 quarters.

Profit

Score:

81/100

Out of the last 20 quarters, DXCM has had 16 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

Score:

46/100

DXCM has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

DexCom, Inc. Summary

Nasdaq / DXCM
Healthcare
Medical - Devices
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.